Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research ...

Sarepta (SRPT) shared updates from its clinical programs focused on limb-girdle muscular dystrophy subtypes 2C/R5, 2D/R3, and 2E/R4. Following ...

Fintel reports that on April 11, 2025, Wells Fargo initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a ...

Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...

Born from a 2013 spinoff of Abbott Laboratories' pharmaceutical business, AbbVie (NYSE:ABBV) is a biopharmaceutical company that develops and markets medications for autoimmune diseases, cancer, ...

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

Mass firings at the U.S. Food and Drug Administration are particularly risky for small- and mid-cap biotech companies that ...